Coya Plans Open-Label Extension of ALSTARS Phase 2/3 Trial
Coya plans to initiate an open-label extension to continue COYA 302 treatment and collect longer-term ALS data. The company also delayed its FTD trial to 2027.
Coya plans to initiate an open-label extension to continue COYA 302 treatment and collect longer-term ALS data. The company also delayed its FTD trial to 2027.